ImmuCell (ICCC) Financials

ImmuCell logo
$11.33 -0.09 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$11.22 -0.11 (-0.97%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for ImmuCell

Annual Income Statements for ImmuCell

This table shows ImmuCell's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1.21 0.51 -0.17 -2.32 -1.30 -1.02 -0.08 -2.49 -5.77 -2.16 -1.04
Consolidated Net Income / (Loss)
1.21 0.51 -0.17 -2.32 -1.30 -1.02 -0.08 -2.49 -5.77 -2.16 -1.04
Net Income / (Loss) Continuing Operations
1.21 0.51 -0.17 -2.32 -1.30 -1.02 -0.08 -2.49 -5.77 -2.16 -1.04
Total Pre-Tax Income
2.06 0.76 -0.44 -1.86 -1.27 -1.03 -0.07 -2.49 -5.77 -2.15 -1.03
Total Operating Income
2.12 0.89 -0.24 -1.45 -0.95 -1.38 0.26 -2.30 -5.75 -1.64 1.65
Total Gross Profit
6.25 5.42 5.22 5.19 6.74 6.86 8.66 7.65 3.87 7.94 11
Total Revenue
10 9.54 10 11 14 15 19 19 17 26 28
Operating Revenue
10 9.54 10 11 14 15 19 19 17 26 28
Total Cost of Revenue
3.98 4.12 5.21 5.79 6.98 8.48 11 11 14 19 16
Operating Cost of Revenue
3.98 4.12 5.21 5.79 6.98 8.48 11 11 14 19 16
Total Operating Expenses
4.13 4.53 5.46 6.64 7.69 8.24 8.40 9.95 9.62 9.58 9.80
Selling, General & Admin Expense
1.29 1.45 1.52 1.74 1.69 1.72 1.73 2.26 2.13 2.22 3.20
Marketing Expense
1.61 1.83 1.89 2.08 2.32 2.17 2.50 3.19 3.09 3.47 3.55
Research & Development Expense
1.24 1.24 2.05 3.52 3.69 4.35 4.17 4.49 4.39 3.90 3.04
Total Other Income / (Expense), net
-0.06 -0.13 -0.20 -0.41 -0.31 0.35 -0.33 -0.19 -0.02 -0.51 -2.68
Other Income / (Expense), net
-0.06 -0.13 -0.20 -0.41 -0.31 0.35 -0.33 -0.19 -0.02 -0.51 -2.68
Income Tax Expense
0.85 0.25 -0.27 0.46 0.03 -0.01 0.01 0.01 0.00 0.01 0.01
Basic Earnings per Share
$0.40 $0.12 ($0.03) ($0.42) ($0.19) ($0.14) ($0.01) ($0.32) ($0.75) ($0.26) ($0.12)
Weighted Average Basic Shares Outstanding
3.04M 4.23M 4.95M 5.49M 6.82M 7.21M 7.59M 7.75M 7.75M 8.17M 9.03M
Diluted Earnings per Share
$0.38 $0.12 ($0.03) ($0.42) ($0.19) ($0.14) ($0.01) ($0.32) ($0.75) ($0.26) ($0.12)
Weighted Average Diluted Shares Outstanding
3.17M 4.34M 4.95M 5.49M 6.82M 7.21M 7.59M 7.75M 7.75M 8.17M 9.03M
Weighted Average Basic & Diluted Shares Outstanding
4.18M 4.85M 5.48M 5.57M 7.21M 7.22M 7.74M 7.75M 7.75M 8.98M 9.05M

Quarterly Income Statements for ImmuCell

This table shows ImmuCell's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-0.44 -1.53 -0.70 0.51 1.45 0.50 -0.14 -2.85 1.94 1.83 0.95
Consolidated Net Income / (Loss)
-0.44 -1.53 -0.70 0.51 1.45 0.50 -0.14 -2.85 1.94 1.83 0.95
Net Income / (Loss) Continuing Operations
-0.44 -1.53 -0.70 0.51 1.45 0.50 -0.14 -2.85 1.94 1.83 0.95
Total Pre-Tax Income
-0.44 -1.53 -0.70 0.52 1.45 0.50 -0.14 -2.85 1.95 1.88 0.94
Total Operating Income
-0.30 -1.39 -0.57 0.62 1.12 0.57 0.02 -0.06 1.97 1.93 0.96
Total Gross Profit
2.30 1.23 1.58 2.83 3.35 2.82 2.36 2.91 4.66 2.44 3.56
Total Revenue
7.26 5.47 6.01 7.75 8.07 6.44 5.51 7.63 10 7.19 8.04
Operating Revenue
7.26 5.47 6.01 7.75 8.07 6.44 5.51 7.63 10 7.19 8.04
Total Cost of Revenue
4.96 4.24 4.43 4.92 4.71 3.63 3.14 4.72 5.70 4.75 4.48
Operating Cost of Revenue
4.96 4.24 4.43 4.92 4.71 3.63 3.14 4.72 5.70 4.75 4.48
Total Operating Expenses
2.60 2.62 2.16 2.21 2.24 2.25 2.34 2.97 2.69 0.50 2.60
Selling, General & Admin Expense
0.53 0.60 0.53 0.55 0.62 0.72 0.73 1.13 1.14 1.27 1.29
Marketing Expense
0.80 0.98 0.84 0.84 0.86 0.70 0.92 1.08 1.23 1.11 1.13
Research & Development Expense
1.26 1.03 0.79 0.82 0.76 0.83 0.69 0.76 0.32 0.12 0.18
Other Operating Expenses / (Income)
- - - - - 0.00 0.00 - - -2.00 0.00
Total Other Income / (Expense), net
-0.14 -0.14 -0.13 -0.10 0.33 -0.07 -0.16 -2.79 -0.02 -0.05 -0.02
Other Income / (Expense), net
-0.14 -0.14 -0.13 -0.10 0.33 -0.07 -0.16 -2.79 -0.02 -0.05 -0.02
Income Tax Expense
0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.05 -0.02
Basic Earnings per Share
($0.06) ($0.20) ($0.09) $0.09 $0.16 $0.06 ($0.02) ($0.32) $0.21 $0.20 $0.10
Weighted Average Basic Shares Outstanding
7.75M 7.81M 8.16M 8.17M 8.98M 9.03M 9.05M 9.03M 9.05M 9.06M 9.08M
Diluted Earnings per Share
($0.06) ($0.20) ($0.09) $0.09 $0.16 $0.06 ($0.02) ($0.32) $0.21 $0.20 $0.10
Weighted Average Diluted Shares Outstanding
7.75M 7.81M 8.16M 8.17M 8.98M 9.03M 9.05M 9.03M 9.05M 9.19M 9.30M
Weighted Average Basic & Diluted Shares Outstanding
7.81M 7.83M 8.91M 8.98M - 9.05M 9.05M 9.05M 9.05M 9.08M 9.09M

Annual Cash Flow Statements for ImmuCell

This table details how cash moves in and out of ImmuCell's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
0.72 3.58 -1.35 -1.28 3.77 0.66 3.24 -4.39 -4.81 2.78 0.05
Net Cash From Operating Activities
2.90 -0.22 1.18 -0.37 0.23 1.32 0.95 -1.54 -4.67 0.36 2.48
Net Cash From Continuing Operating Activities
2.90 -0.22 1.18 -0.37 0.23 1.32 0.95 -1.54 -4.67 0.36 2.48
Net Income / (Loss) Continuing Operations
1.21 0.51 -0.17 -2.32 -1.30 -1.02 -0.08 -2.49 -5.77 -2.16 -1.04
Consolidated Net Income / (Loss)
1.21 0.51 -0.17 -2.32 -1.30 -1.02 -0.08 -2.49 -5.77 -2.16 -1.04
Depreciation Expense
0.53 0.78 0.89 1.50 2.25 2.33 2.44 2.47 2.70 2.67 2.71
Amortization Expense
0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.04 0.06 0.07
Non-Cash Adjustments To Reconcile Net Income
0.02 0.10 0.19 -0.34 0.33 -0.53 0.19 0.29 0.47 0.19 2.78
Changes in Operating Assets and Liabilities, net
1.14 -1.64 0.25 0.76 -1.07 0.52 -1.62 -1.83 -2.11 -0.41 -2.05
Net Cash From Investing Activities
-4.62 -4.52 -12 -1.79 -3.40 -2.57 -1.60 -3.96 -1.89 -0.46 -1.21
Net Cash From Continuing Investing Activities
-4.62 -4.52 -12 -1.79 -3.40 -2.57 -1.60 -3.96 -1.89 -0.46 -1.21
Purchase of Property, Plant & Equipment
-2.72 -4.05 -18 -2.03 -1.39 -4.07 -2.61 -3.98 -1.89 -0.47 -1.25
Sale of Property, Plant & Equipment
0.07 0.03 0.05 - 0.45 0.05 0.02 0.01 0.00 0.00 0.04
Net Cash From Financing Activities
2.44 8.32 9.75 0.89 6.94 1.91 3.88 1.11 1.75 2.88 -1.21
Net Cash From Continuing Financing Activities
2.44 8.32 9.75 0.89 6.94 1.91 3.88 1.11 1.75 2.88 -1.21
Repayment of Debt
-0.20 -0.18 -0.22 -0.40 -1.36 -9.63 -0.77 -0.92 -3.27 -1.47 -2.30
Repurchase of Common Equity
- - - - - - - - 0.00 -0.29 -0.07
Issuance of Debt
2.50 0.00 6.15 1.19 0.00 12 0.40 2.00 5.00 0.00 0.80
Issuance of Common Equity
0.00 8.47 3.77 0.00 8.30 0.00 4.23 - 0.00 4.65 0.35
Other Financing Activities, net
0.15 0.03 0.05 0.10 0.00 0.00 0.01 0.03 0.02 0.00 0.00
Cash Interest Paid
0.08 0.15 0.19 0.40 0.42 0.48 0.31 0.34 0.44 0.53 0.44
Cash Income Taxes Paid
0.00 0.12 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01

Quarterly Cash Flow Statements for ImmuCell

This table details how cash moves in and out of ImmuCell's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-0.02 0.36 2.48 -0.05 0.84 1.40 -2.11 -0.08 3.01 2.05 -0.95
Net Cash From Operating Activities
0.42 0.58 -0.64 -0.00 1.57 1.60 -1.18 0.48 3.57 3.02 0.76
Net Cash From Continuing Operating Activities
0.42 0.58 -0.64 -0.00 1.57 1.60 -1.18 0.48 3.57 3.02 0.76
Net Income / (Loss) Continuing Operations
-0.44 -1.53 -0.70 0.51 1.45 0.50 -0.14 -2.85 1.94 1.83 0.95
Consolidated Net Income / (Loss)
-0.44 -1.53 -0.70 0.51 1.45 0.50 -0.14 -2.85 1.94 1.83 0.95
Depreciation Expense
0.66 0.67 0.67 0.67 0.67 0.66 0.67 0.70 0.53 0.47 0.46
Amortization Expense
0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.01 0.00 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
0.04 0.08 0.04 0.03 0.02 0.02 -0.09 2.84 0.15 0.26 0.41
Changes in Operating Assets and Liabilities, net
0.14 1.36 -0.66 -1.23 -0.58 0.40 -1.66 -0.22 0.95 0.45 -1.07
Net Cash From Investing Activities
-0.07 -0.11 -0.09 -0.20 -0.33 -0.13 -0.59 -0.17 -0.17 -0.73 -1.35
Net Cash From Continuing Investing Activities
-0.07 -0.11 -0.09 -0.20 -0.33 -0.13 -0.59 -0.17 -0.17 -0.73 -1.35
Purchase of Property, Plant & Equipment
-0.07 -0.11 -0.09 -0.20 -0.33 -0.16 -0.59 -0.17 -0.18 -0.73 -1.35
Net Cash From Financing Activities
-0.37 -0.11 3.21 0.15 -0.40 -0.08 -0.34 -0.39 -0.40 -0.24 -0.36
Net Cash From Continuing Financing Activities
-0.37 -0.11 3.21 0.15 -0.40 -0.08 -0.34 -0.39 -0.40 -0.24 -0.36
Repayment of Debt
-0.37 -0.36 -0.37 -0.37 -0.38 -0.38 -1.14 -0.39 -0.40 -0.40 -0.41
Other Financing Activities, net
- - - - 0.00 - - - 0.00 0.16 0.05
Cash Interest Paid
0.14 0.13 0.13 0.12 0.12 0.12 0.11 0.10 0.10 0.09 0.09
Cash Income Taxes Paid
- - - 0.00 0.00 - - 0.00 0.01 - 0.07

Annual Balance Sheets for ImmuCell

This table presents ImmuCell's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
15 25 34 33 39 40 44 45 44 45 43
Total Current Assets
7.88 14 7.51 6.42 13 12 16 14 11 15 17
Cash & Equivalents
1.57 5.15 3.80 2.52 6.29 6.95 10 5.79 0.98 3.76 3.81
Accounts Receivable
0.72 0.99 1.34 0.93 1.64 1.80 2.69 1.76 2.19 3.77 3.42
Inventories, net
0.87 2.13 2.05 2.33 2.52 2.09 3.09 6.04 7.81 7.11 9.27
Prepaid Expenses
0.25 0.60 0.31 0.64 0.26 0.32 0.30 0.41 0.49 0.40 0.45
Plant, Property, & Equipment, net
5.72 9.85 26 26 25 27 27 28 28 25 21
Total Noncurrent Assets
0.94 0.50 0.72 0.28 0.24 1.44 1.31 2.35 4.76 4.71 4.51
Goodwill
0.00 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Other Noncurrent Operating Assets
0.00 0.03 0.00 0.05 0.03 1.25 1.14 2.19 4.63 4.59 4.42
Total Liabilities & Shareholders' Equity
15 25 34 33 39 40 44 45 44 45 43
Total Liabilities
3.93 4.98 11 11 9.70 12 12 14 19 18 15
Total Current Liabilities
0.79 2.06 2.06 2.57 2.50 2.21 2.53 3.07 4.20 4.41 3.98
Short-Term Debt
0.13 0.13 0.32 1.34 1.27 0.76 0.81 1.04 1.43 1.50 1.61
Accounts Payable
- 1.89 1.72 1.22 1.22 1.35 1.61 2.00 2.12 2.48 2.28
Other Current Liabilities
0.66 - - - 0.00 0.10 0.11 0.03 0.64 0.43 0.09
Total Noncurrent Liabilities
3.13 2.92 8.64 8.42 7.21 9.87 9.35 11 15 13 11
Long-Term Debt
3.05 2.88 8.64 8.42 7.15 8.74 8.33 9.19 11 9.04 7.49
Other Noncurrent Operating Liabilities
0.08 0.04 0.00 0.00 0.06 1.14 1.03 2.22 4.08 4.13 4.01
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
11 20 24 22 29 28 33 30 25 28 27
Total Preferred & Common Equity
11 20 24 22 29 28 33 30 25 28 27
Total Common Equity
11 20 24 22 29 28 33 30 25 28 27
Common Stock
10 19 23 23 32 32 36 37 37 42 42
Retained Earnings
0.64 1.15 0.98 -1.34 -2.64 -3.66 -3.74 -6.23 -12 -14 -15
Treasury Stock
-0.45 -0.43 -0.41 -0.20 -0.19 -0.18 -0.16 -0.15 -0.14 -0.14 -0.13

Quarterly Balance Sheets for ImmuCell

This table presents ImmuCell's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
45 43 42 44 46 47 46 44 47 48
Total Current Assets
12 11 11 14 16 17 17 19 21 22
Cash & Equivalents
1.99 0.96 1.32 3.81 4.60 6.00 3.89 6.81 8.86 7.91
Accounts Receivable
1.86 2.62 1.95 2.31 3.35 2.38 2.55 2.69 2.90 3.37
Inventories, net
7.39 7.15 7.30 7.46 7.36 8.29 9.80 8.67 9.08 9.86
Prepaid Expenses
0.72 0.62 0.22 0.31 0.62 0.46 0.58 0.68 0.24 0.43
Plant, Property, & Equipment, net
28 27 26 26 25 25 24 21 21 22
Total Noncurrent Assets
4.42 4.72 4.66 4.74 4.68 4.70 4.56 4.47 4.52 4.46
Goodwill
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
Other Noncurrent Operating Assets
4.29 4.59 4.54 4.62 4.57 4.60 4.46 4.37 4.42 4.37
Total Liabilities & Shareholders' Equity
45 43 42 44 46 47 46 44 47 48
Total Liabilities
19 18 18 18 17 17 16 15 15 15
Total Current Liabilities
3.33 4.18 4.56 4.47 3.87 4.45 4.00 3.91 4.44 4.68
Short-Term Debt
1.41 1.44 1.46 1.48 1.52 1.54 1.59 1.63 1.51 1.38
Accounts Payable
1.85 2.14 2.56 2.50 1.97 2.59 2.32 2.20 2.81 3.17
Other Current Liabilities
0.07 0.60 0.53 0.48 0.38 0.32 0.08 0.09 0.12 0.12
Total Noncurrent Liabilities
15 14 14 14 13 12 12 11 11 11
Long-Term Debt
11 10 9.80 9.42 8.65 8.26 7.90 7.07 6.80 6.52
Other Noncurrent Operating Liabilities
4.30 4.06 4.04 4.15 4.11 4.14 4.03 3.99 4.02 3.99
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
26 25 23 26 29 30 30 29 31 33
Total Preferred & Common Equity
26 25 23 26 29 30 30 29 31 33
Total Common Equity
26 25 23 26 29 30 30 29 31 33
Common Stock
37 37 38 41 42 42 42 43 43 43
Retained Earnings
-11 -12 -14 -15 -13 -12 -12 -13 -11 -10
Treasury Stock
-0.15 -0.14 -0.14 -0.14 -0.14 -0.13 -0.13 -0.19 -0.08 -0.05

Annual Metrics And Ratios for ImmuCell

This table displays calculated financial ratios and metrics derived from ImmuCell's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
3,055,034.00 4,847,390.00 5,051,390.00 5,484,728.00 7,209,595.00 7,212,919.00 7,741,864.00 7,746,864.00 7,750,864.00 7,750,864.00 9,045,851.00
DEI Adjusted Shares Outstanding
3,055,034.00 4,847,390.00 5,051,390.00 5,484,728.00 7,209,595.00 7,212,919.00 7,741,864.00 7,746,864.00 7,750,864.00 7,750,864.00 9,045,851.00
DEI Earnings Per Adjusted Shares Outstanding
0.40 0.10 -0.03 -0.42 -0.18 -0.14 -0.01 -0.32 -0.75 -0.28 -0.12
Growth Metrics
- - - - - - - - - - -
Revenue Growth
34.64% -6.69% 9.30% 5.32% 24.91% 11.80% 25.43% -3.51% -5.90% 51.64% 4.34%
EBITDA Growth
1,238.43% -39.73% -70.14% -172.83% 394.69% 31.50% 81.90% -99.62% -33,371.31% 119.25% 200.97%
EBIT Growth
907.81% -63.25% -157.82% -324.20% 31.86% 18.55% 93.30% -3,496.47% -132.09% 62.80% 52.09%
NOPAT Growth
963.65% -52.17% -128.48% -495.68% 34.06% -44.71% 118.65% -993.19% -150.03% 71.47% 200.56%
Net Income Growth
825.80% -58.09% -133.07% -1,280.74% 44.20% 21.11% 92.34% -3,085.26% -131.56% 62.65% 51.78%
EPS Growth
733.33% -68.42% -125.00% -1,300.00% 54.76% 26.32% 92.86% -3,100.00% -134.38% 65.33% 53.85%
Operating Cash Flow Growth
859.19% -107.67% 628.90% -131.76% 162.54% 463.39% -27.47% -261.80% -202.76% 107.66% 591.61%
Free Cash Flow Firm Growth
124.37% -1,509.03% -295.86% 92.57% 74.61% -575.93% 28.51% -219.39% -5.94% 110.35% 478.29%
Invested Capital Growth
14.98% 66.66% 137.42% 0.83% -1.21% 4.12% 5.75% 10.43% 3.34% -4.68% -5.69%
Revenue Q/Q Growth
5.02% -4.79% 9.66% -1.75% 5.34% 0.73% 9.69% -7.63% 7.28% 11.14% -0.45%
EBITDA Q/Q Growth
11.67% -15.60% -52.58% -240.18% 254.21% 73.92% -5.17% -99.48% 16.68% 154.23% -65.56%
EBIT Q/Q Growth
13.24% -32.26% -455.80% -41.40% 36.34% 32.96% -241.24% -233.92% 8.38% 43.60% -143.99%
NOPAT Q/Q Growth
15.88% -29.31% -227.29% -54.87% 41.74% -39.65% 146.37% -342.30% 9.88% 49.77% -50.12%
Net Income Q/Q Growth
14.99% -33.71% -396.08% -58.57% 36.41% 32.82% -315.06% -231.71% 8.38% 43.41% -144.76%
EPS Q/Q Growth
15.15% -42.86% 0.00% -55.56% 38.71% 39.13% -200.00% -255.56% 8.54% 48.00% -141.38%
Operating Cash Flow Q/Q Growth
24.90% -122.69% 148.55% -490.38% 64.69% 18.23% 82.61% -551.63% 10.95% 198.84% 24.41%
Free Cash Flow Firm Q/Q Growth
178.46% -100.47% -15.61% 78.78% -192.65% 27.17% -31.60% -81.59% 27.67% -2.26% 649.57%
Invested Capital Q/Q Growth
5.57% 23.00% 17.25% -2.58% 1.31% -2.31% 0.74% 3.53% -0.98% 2.37% -8.64%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
61.11% 56.80% 50.06% 47.28% 49.11% 44.73% 44.98% 41.19% 22.15% 29.97% 41.40%
EBITDA Margin
25.32% 16.35% 4.47% -3.09% 7.29% 8.57% 12.43% 0.05% -17.34% 2.20% 6.35%
Operating Margin
20.75% 9.33% -2.33% -13.17% -6.95% -9.00% 1.34% -12.38% -32.90% -6.19% 5.97%
EBIT Margin
20.17% 7.95% -4.20% -16.93% -9.24% -6.73% -0.36% -13.39% -33.02% -8.10% -3.72%
Profit (Net Income) Margin
11.86% 5.33% -1.61% -21.13% -9.44% -6.66% -0.41% -13.43% -33.05% -8.14% -3.76%
Tax Burden Percent
58.79% 67.05% 38.35% 124.82% 102.22% 99.02% 113.26% 100.31% 100.08% 100.47% 101.13%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
41.21% 32.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
18.37% 6.16% -0.83% -3.51% -2.32% -3.31% 0.59% -4.85% -11.37% -3.27% 3.46%
ROIC Less NNEP Spread (ROIC-NNEP)
19.47% 7.77% -0.98% -24.62% -20.54% -12.63% -101.79% -56.99% -34.06% -14.62% -32.89%
Return on Net Nonoperating Assets (RNNOA)
-6.16% -2.81% 0.06% -6.73% -2.79% -0.26% -0.84% -3.07% -9.49% -4.95% -7.28%
Return on Equity (ROE)
12.21% 3.35% -0.78% -10.24% -5.11% -3.57% -0.26% -7.92% -20.86% -8.21% -3.81%
Cash Return on Invested Capital (CROIC)
4.44% -43.84% -82.29% -4.33% -1.10% -7.34% -5.00% -14.76% -14.66% 1.53% 9.32%
Operating Return on Assets (OROA)
16.13% 3.87% -1.49% -5.55% -3.55% -2.61% -0.16% -5.57% -13.01% -4.83% -2.35%
Return on Assets (ROA)
9.48% 2.59% -0.57% -6.93% -3.63% -2.59% -0.18% -5.58% -13.03% -4.85% -2.37%
Return on Common Equity (ROCE)
12.21% 3.35% -0.78% -10.24% -5.11% -3.57% -0.26% -7.92% -20.86% -8.21% -3.81%
Return on Equity Simple (ROE_SIMPLE)
11.43% 2.58% -0.71% -10.68% -4.47% -3.62% -0.24% -8.21% -23.10% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1.25 0.60 -0.17 -1.01 -0.67 -0.97 0.18 -1.61 -4.02 -1.15 1.15
NOPAT Margin
12.20% 6.25% -1.63% -9.22% -4.87% -6.30% 0.94% -8.67% -23.03% -4.33% 4.18%
Net Nonoperating Expense Percent (NNEP)
-1.10% -1.61% 0.15% 21.11% 18.22% 9.32% 102.38% 52.14% 22.70% 11.35% 36.36%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -10.89% -3.02% 3.19%
Cost of Revenue to Revenue
38.89% 43.20% 49.94% 52.72% 50.89% 55.27% 55.02% 58.81% 77.85% 70.03% 58.60%
SG&A Expenses to Revenue
12.58% 15.24% 14.62% 15.83% 12.30% 11.22% 8.97% 12.19% 12.22% 8.37% 11.58%
R&D to Revenue
12.08% 13.04% 19.62% 32.01% 26.87% 28.38% 21.66% 24.20% 25.15% 14.72% 11.00%
Operating Expenses to Revenue
40.36% 47.47% 52.38% 60.44% 56.06% 53.73% 43.64% 53.57% 55.05% 36.16% 35.44%
Earnings before Interest and Taxes (EBIT)
2.06 0.76 -0.44 -1.86 -1.27 -1.03 -0.07 -2.49 -5.77 -2.15 -1.03
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2.59 1.56 0.47 -0.34 1.00 1.32 2.39 0.01 -3.03 0.58 1.76
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
2.25 1.31 1.84 1.78 1.21 1.52 1.86 1.56 1.58 1.53 2.05
Price to Tangible Book Value (P/TBV)
2.25 1.33 1.86 1.80 1.22 1.53 1.87 1.56 1.59 1.53 2.06
Price to Revenue (P/Rev)
2.33 2.70 4.17 3.52 2.56 2.80 3.16 2.54 2.26 1.59 2.01
Price to Earnings (P/E)
19.67 50.74 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
5.08% 1.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.82 1.50 1.69 1.58 1.21 1.49 1.89 1.48 1.40 1.42 1.88
Enterprise Value to Revenue (EV/Rev)
2.01 1.91 4.66 4.18 2.53 2.90 3.10 2.78 2.89 1.84 2.20
Enterprise Value to EBITDA (EV/EBITDA)
7.93 11.65 104.43 0.00 34.76 33.82 24.96 5,674.60 0.00 83.74 34.64
Enterprise Value to EBIT (EV/EBIT)
9.94 23.98 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
16.45 30.47 0.00 0.00 0.00 0.00 331.32 0.00 0.00 0.00 52.67
Enterprise Value to Operating Cash Flow (EV/OCF)
7.08 0.00 41.38 0.00 148.88 33.80 62.56 0.00 0.00 136.47 24.56
Enterprise Value to Free Cash Flow (EV/FCFF)
68.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 90.96 19.58
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.30 0.15 0.38 0.45 0.29 0.34 0.28 0.34 0.48 0.38 0.34
Long-Term Debt to Equity
0.29 0.15 0.37 0.39 0.25 0.31 0.26 0.30 0.42 0.33 0.28
Financial Leverage
-0.32 -0.36 -0.06 0.27 0.14 0.02 0.01 0.05 0.28 0.34 0.22
Leverage Ratio
1.29 1.29 1.36 1.48 1.41 1.38 1.39 1.42 1.60 1.69 1.61
Compound Leverage Factor
1.29 1.29 1.36 1.48 1.41 1.38 1.39 1.42 1.60 1.69 1.61
Debt to Total Capital
23.09% 13.25% 27.51% 30.99% 22.51% 25.15% 21.91% 25.19% 32.38% 27.69% 25.17%
Short-Term Debt to Total Capital
0.95% 0.59% 0.97% 4.27% 3.41% 2.01% 1.95% 2.56% 3.87% 3.94% 4.45%
Long-Term Debt to Total Capital
22.14% 12.66% 26.54% 26.73% 19.10% 23.14% 19.96% 22.63% 28.52% 23.76% 20.71%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
76.91% 86.75% 72.49% 69.01% 77.49% 74.85% 78.09% 74.81% 67.62% 72.31% 74.83%
Debt to EBITDA
1.23 1.93 19.22 -28.78 8.42 7.22 3.82 1,123.25 -3.95 18.07 5.18
Net Debt to EBITDA
-1.29 -4.88 11.07 -21.35 -0.35 1.18 -0.44 487.37 -3.63 11.62 3.01
Long-Term Debt to EBITDA
1.18 1.84 18.54 -24.82 7.15 6.64 3.48 1,009.12 -3.48 15.50 4.27
Debt to NOPAT
2.55 5.05 -52.68 -9.64 -12.61 -9.83 50.73 -6.36 -2.97 -9.18 7.88
Net Debt to NOPAT
-2.68 -12.75 -30.34 -7.15 0.53 -1.61 -5.81 -2.76 -2.73 -5.91 4.58
Long-Term Debt to NOPAT
2.45 4.82 -50.82 -8.32 -10.70 -9.04 46.22 -5.71 -2.62 -7.87 6.49
Altman Z-Score
5.47 4.26 2.93 2.34 2.65 2.60 3.75 2.29 1.04 1.71 2.59
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.94 6.97 3.64 2.50 5.29 5.50 6.42 4.58 2.73 3.41 4.26
Quick Ratio
8.53 5.64 2.49 1.35 4.17 4.41 5.08 2.46 0.75 1.71 1.82
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.30 -4.25 -17 -1.25 -0.32 -2.14 -1.53 -4.90 -5.19 0.54 3.11
Operating Cash Flow to CapEx
109.32% -5.53% 6.64% -18.40% 24.80% 32.67% 36.79% -38.94% -247.31% 77.60% 203.84%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.80 0.49 0.35 0.33 0.38 0.39 0.45 0.42 0.39 0.60 0.63
Accounts Receivable Turnover
11.87 11.16 8.93 9.65 10.68 8.94 8.57 8.34 8.86 8.90 7.69
Inventory Turnover
4.38 2.75 2.49 2.64 2.88 3.68 4.09 2.39 1.96 2.49 1.98
Fixed Asset Turnover
2.14 1.23 0.58 0.42 0.54 0.59 0.72 0.67 0.62 1.00 1.19
Accounts Payable Turnover
0.00 0.00 2.88 3.94 5.72 6.60 7.14 6.04 6.59 8.05 6.80
Days Sales Outstanding (DSO)
30.75 32.71 40.88 37.81 34.17 40.85 42.59 43.77 41.20 41.03 47.47
Days Inventory Outstanding (DIO)
83.32 132.66 146.31 138.04 126.75 99.24 89.34 152.57 185.83 146.81 184.54
Days Payable Outstanding (DPO)
0.00 0.00 126.64 92.75 63.80 55.33 51.10 60.42 55.35 45.32 53.68
Cash Conversion Cycle (CCC)
114.06 165.36 60.55 83.10 97.12 84.75 80.83 135.92 171.68 142.53 178.32
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
7.27 12 29 29 29 30 32 35 36 34 32
Invested Capital Turnover
1.51 0.99 0.51 0.38 0.48 0.52 0.63 0.56 0.49 0.75 0.83
Increase / (Decrease) in Invested Capital
0.95 4.84 17 0.24 -0.35 1.18 1.71 3.29 1.16 -1.69 -1.95
Enterprise Value (EV)
21 18 49 46 35 44 60 52 50 49 61
Market Capitalization
24 26 44 39 35 43 61 47 39 42 56
Book Value per Share
$3.47 $4.07 $4.67 $3.96 $4.02 $3.92 $4.21 $3.92 $3.22 $3.37 $2.99
Tangible Book Value per Share
$3.47 $4.01 $4.62 $3.92 $3.99 $3.89 $4.19 $3.90 $3.21 $3.36 $2.98
Total Capital
14 23 33 32 37 38 42 41 37 38 36
Total Debt
3.19 3.01 8.96 9.77 8.42 9.50 9.14 10 12 11 9.10
Total Long-Term Debt
3.05 2.88 8.64 8.42 7.15 8.74 8.33 9.19 11 9.04 7.49
Net Debt
-3.35 -7.61 5.16 7.24 -0.35 1.55 -1.05 4.44 11 6.78 5.29
Capital Expenditures (CapEx)
2.65 4.02 18 2.03 0.94 4.03 2.59 3.96 1.89 0.46 1.21
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1.17 1.80 1.96 2.68 3.19 2.76 4.36 6.25 7.72 8.37 11
Debt-free Net Working Capital (DFNWC)
7.22 12 5.76 5.20 12 11 15 12 8.70 12 15
Net Working Capital (NWC)
7.09 12 5.44 3.86 11 9.95 14 11 7.27 11 13
Net Nonoperating Expense (NNE)
0.03 0.09 -0.00 1.31 0.63 0.06 0.26 0.88 1.75 1.01 2.19
Net Nonoperating Obligations (NNO)
-3.35 -7.61 5.16 7.24 -0.35 1.55 -1.05 4.44 11 6.78 5.29
Total Depreciation and Amortization (D&A)
0.53 0.80 0.90 1.52 2.27 2.35 2.46 2.50 2.74 2.73 2.78
Debt-free, Cash-free Net Working Capital to Revenue
11.47% 18.84% 18.80% 24.39% 23.28% 17.99% 22.64% 33.65% 44.20% 31.59% 38.96%
Debt-free Net Working Capital to Revenue
70.56% 130.16% 55.22% 47.33% 87.22% 69.78% 75.57% 64.84% 49.80% 45.78% 52.73%
Net Working Capital to Revenue
69.28% 128.76% 52.18% 35.10% 77.93% 64.83% 71.35% 59.24% 41.62% 40.13% 46.91%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.40 $0.12 ($0.03) ($0.42) ($0.19) ($0.14) ($0.01) ($0.32) ($0.75) ($0.26) ($0.12)
Adjusted Weighted Average Basic Shares Outstanding
3.04M 4.23M 4.95M 5.49M 6.82M 7.21M 7.59M 7.75M 7.75M 8.17M 9.03M
Adjusted Diluted Earnings per Share
$0.38 $0.12 ($0.03) ($0.42) ($0.19) ($0.14) ($0.01) ($0.32) ($0.75) ($0.26) ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding
3.17M 4.34M 4.95M 5.49M 6.82M 7.21M 7.59M 7.75M 7.75M 8.17M 9.03M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
4.18M 4.85M 5.48M 5.57M 7.21M 7.22M 7.74M 7.75M 7.75M 8.98M 9.05M
Normalized Net Operating Profit after Tax (NOPAT)
1.25 0.60 -0.17 -1.50 -0.67 -0.97 0.18 -1.61 -4.02 -1.15 1.15
Normalized NOPAT Margin
12.20% 6.25% -1.63% -13.68% -4.87% -6.30% 0.94% -8.67% -23.03% -4.33% 4.18%
Pre Tax Income Margin
20.17% 7.95% -4.20% -16.93% -9.24% -6.73% -0.36% -13.39% -33.02% -8.10% -3.72%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13.53% -6.53%

Quarterly Metrics And Ratios for ImmuCell

This table displays calculated financial ratios and metrics derived from ImmuCell's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 9,045,851.00 9,046,799.00 9,046,799.00 9,082,197.00
DEI Adjusted Shares Outstanding
7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 7,750,864.00 9,045,851.00 9,046,799.00 9,046,799.00 9,082,197.00
DEI Earnings Per Adjusted Shares Outstanding
-0.06 -0.20 -0.09 0.07 0.19 0.06 -0.02 -0.32 0.21 0.20 0.10
Growth Metrics
- - - - - - - - - - -
Revenue Growth
110.58% 54.92% 11.40% 52.10% 11.16% 17.76% -8.41% -1.61% 28.39% 11.50% 46.02%
EBITDA Growth
114.56% -22.71% 93.75% 365.76% 786.27% 239.40% 4,075.42% -277.26% 16.38% 99.05% 143.77%
EBIT Growth
81.13% -11.04% 25.48% 145.73% 431.91% 132.92% 80.68% -646.65% 34.87% 273.30% 791.30%
NOPAT Growth
86.70% -6.29% 51.45% 187.44% 631.41% 158.46% 103.49% -106.61% 75.31% 232.68% 6,841.25%
Net Income Growth
81.09% -11.01% 25.35% 145.14% 430.46% 132.77% 80.08% -653.71% 34.18% 265.56% 781.59%
EPS Growth
80.00% -11.11% 25.00% 160.00% 366.67% 130.00% 77.78% -455.56% 31.25% 233.33% 600.00%
Operating Cash Flow Growth
115.15% 185.38% -25.91% 99.58% 276.06% 175.28% -84.97% 15,915.83% 127.03% 88.52% 163.92%
Free Cash Flow Firm Growth
110.19% 136.63% 168.77% 223.15% 236.54% -83.61% -177.54% -16.92% 198.46% 1,531.25% 292.04%
Invested Capital Growth
-2.10% -7.59% -7.80% -4.68% -2.06% 0.83% 5.67% -5.69% -10.24% -8.47% -7.48%
Revenue Q/Q Growth
42.42% -24.59% 9.84% 28.94% 4.08% -20.11% -14.57% 38.50% 35.82% -30.62% 11.88%
EBITDA Q/Q Growth
153.14% -452.12% 98.30% 8,456.42% 77.20% -44.62% -51.52% -472.59% 216.35% -5.28% -40.63%
EBIT Q/Q Growth
61.66% -250.56% 54.23% 174.33% 178.32% -65.23% -126.86% -2,003.48% 168.67% -3.76% -50.27%
NOPAT Q/Q Growth
70.10% -362.12% 58.54% 252.62% 81.73% -49.16% -97.52% -388.70% 4,923.11% -3.53% -48.33%
Net Income Q/Q Growth
61.58% -249.79% 54.19% 173.33% 181.21% -65.32% -127.84% -1,938.77% 168.15% -5.51% -48.08%
EPS Q/Q Growth
60.00% -233.33% 55.00% 200.00% 77.78% -62.50% -133.33% -1,500.00% 165.63% -4.76% -50.00%
Operating Cash Flow Q/Q Growth
157.88% 39.01% -209.89% 99.52% 51,684.27% 1.76% -173.84% 140.80% 640.46% -15.50% -74.96%
Free Cash Flow Firm Q/Q Growth
129.31% 223.97% 37.23% -5.48% -19.92% -84.23% -749.36% 201.28% 187.70% -13.79% -23.56%
Invested Capital Q/Q Growth
-1.93% -5.38% 0.34% 2.37% 0.77% -2.59% 5.16% -8.64% -4.09% -0.67% 6.30%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
31.63% 22.48% 26.34% 36.53% 41.58% 43.72% 42.92% 38.16% 44.97% 33.92% 44.22%
EBITDA Margin
3.32% -15.50% -0.24% 15.55% 26.47% 18.35% 10.41% -28.01% 24.00% 32.76% 17.38%
Operating Margin
-4.13% -25.34% -9.56% 8.02% 13.85% 8.84% 0.36% -0.76% 19.01% 26.93% 11.91%
EBIT Margin
-6.01% -27.96% -11.65% 6.72% 17.96% 7.82% -2.46% -37.32% 18.87% 26.17% 11.63%
Profit (Net Income) Margin
-6.03% -27.99% -11.67% 6.64% 17.94% 7.79% -2.54% -37.36% 18.75% 25.53% 11.85%
Tax Burden Percent
100.31% 100.09% 100.19% 98.84% 99.87% 99.62% 103.29% 100.12% 99.36% 97.56% 101.84%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 1.16% 0.13% 0.38% 0.00% 0.00% 0.64% 2.44% -1.84%
Return on Invested Capital (ROIC)
-1.73% -11.85% -4.57% 5.97% 10.82% 7.42% 0.21% -0.44% 17.24% 24.99% 11.82%
ROIC Less NNEP Spread (ROIC-NNEP)
-4.18% -17.69% -8.01% 4.85% 14.89% 6.47% -2.22% -46.97% 16.84% 21.72% 11.00%
Return on Net Nonoperating Assets (RNNOA)
-1.47% -6.75% -2.66% 1.64% 4.51% 1.67% -0.50% -10.39% 2.16% 1.15% 0.98%
Return on Equity (ROE)
-3.20% -18.60% -7.23% 7.62% 15.32% 9.09% -0.30% -10.83% 19.41% 26.14% 12.80%
Cash Return on Invested Capital (CROIC)
-5.32% 0.09% 1.57% 1.53% 1.63% 4.31% 1.20% 9.32% 16.13% 19.90% 21.53%
Operating Return on Assets (OROA)
-2.97% -15.13% -6.24% 4.00% 11.06% 4.99% -1.51% -23.54% 12.59% 17.20% 8.25%
Return on Assets (ROA)
-2.98% -15.14% -6.25% 3.96% 11.05% 4.97% -1.56% -23.57% 12.51% 16.78% 8.40%
Return on Common Equity (ROCE)
-3.20% -18.60% -7.23% 7.62% 15.32% 9.09% -0.30% -10.83% 19.41% 26.14% 12.80%
Return on Equity Simple (ROE_SIMPLE)
-15.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-0.21 -0.97 -0.40 0.61 1.12 0.57 0.01 -0.04 1.96 1.89 0.98
NOPAT Margin
-2.89% -17.74% -6.69% 7.92% 13.84% 8.80% 0.26% -0.53% 18.89% 26.27% 12.13%
Net Nonoperating Expense Percent (NNEP)
2.46% 5.84% 3.44% 1.12% -4.08% 0.95% 2.42% 46.53% 0.40% 3.27% 0.82%
Return On Investment Capital (ROIC_SIMPLE)
-0.58% -2.80% -1.08% 1.61% 2.85% 1.43% 0.04% -0.11% 5.17% 4.76% 2.40%
Cost of Revenue to Revenue
68.37% 77.52% 73.66% 63.47% 58.42% 56.28% 57.08% 61.84% 55.03% 66.08% 55.78%
SG&A Expenses to Revenue
7.33% 10.99% 8.79% 7.16% 7.72% 11.18% 13.25% 14.79% 10.98% 17.70% 16.04%
R&D to Revenue
17.40% 18.83% 13.08% 10.57% 9.38% 12.91% 12.61% 9.95% 3.07% 1.67% 2.20%
Operating Expenses to Revenue
35.76% 47.82% 35.90% 28.52% 27.72% 34.89% 42.55% 38.92% 25.95% 6.99% 32.30%
Earnings before Interest and Taxes (EBIT)
-0.44 -1.53 -0.70 0.52 1.45 0.50 -0.14 -2.85 1.95 1.88 0.94
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
0.24 -0.85 -0.01 1.21 2.14 1.18 0.57 -2.14 2.49 2.35 1.40
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.67 1.61 1.12 1.53 1.48 2.10 1.90 2.05 1.97 2.94 2.78
Price to Tangible Book Value (P/TBV)
1.68 1.62 1.13 1.53 1.49 2.11 1.90 2.06 1.97 2.95 2.79
Price to Revenue (P/Rev)
1.93 1.63 1.24 1.59 1.58 2.22 2.04 2.01 1.91 3.01 2.74
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 35.68 24.33 0.00 0.00 117.29 48.48
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 2.80% 4.11% 0.00% 0.00% 0.85% 2.06%
Enterprise Value to Invested Capital (EV/IC)
1.47 1.43 1.10 1.42 1.41 1.98 1.76 1.88 1.91 2.98 2.78
Enterprise Value to Revenue (EV/Rev)
2.43 2.06 1.54 1.84 1.78 2.36 2.24 2.20 1.98 2.99 2.74
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 83.74 19.61 14.78 12.19 34.64 28.09 28.01 22.21
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 37.60 26.58 0.00 0.00 107.54 47.35
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 38.69 26.85 52.67 33.79 25.74 19.41
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 136.47 32.11 26.32 31.23 24.56 13.22 15.58 11.63
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 1,528.68 66.85 90.96 85.32 46.10 150.00 19.58 11.18 14.31 12.41
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.47 0.48 0.41 0.38 0.35 0.33 0.32 0.34 0.30 0.26 0.24
Long-Term Debt to Equity
0.41 0.42 0.36 0.33 0.30 0.28 0.27 0.28 0.24 0.22 0.20
Financial Leverage
0.35 0.38 0.33 0.34 0.30 0.26 0.23 0.22 0.13 0.05 0.09
Leverage Ratio
1.63 1.71 1.70 1.69 1.65 1.66 1.60 1.61 1.54 1.52 1.50
Compound Leverage Factor
1.63 1.71 1.70 1.69 1.65 1.66 1.60 1.61 1.54 1.52 1.50
Debt to Total Capital
32.04% 32.43% 29.22% 27.69% 25.97% 24.70% 24.15% 25.17% 23.00% 20.93% 19.42%
Short-Term Debt to Total Capital
3.98% 4.21% 3.96% 3.94% 3.87% 3.87% 4.05% 4.45% 4.30% 3.80% 3.40%
Long-Term Debt to Total Capital
28.05% 28.22% 25.25% 23.76% 22.09% 20.83% 20.10% 20.71% 18.70% 17.13% 16.02%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
67.96% 67.57% 70.78% 72.31% 74.03% 75.30% 75.85% 74.83% 77.00% 79.07% 80.58%
Debt to EBITDA
-10.23 -8.72 -10.14 18.07 4.10 2.17 1.86 5.18 4.13 2.53 1.93
Net Debt to EBITDA
-9.39 -7.69 -6.60 11.62 2.25 0.84 1.10 3.01 0.90 -0.17 0.00
Long-Term Debt to EBITDA
-8.96 -7.59 -8.76 15.50 3.49 1.83 1.55 4.27 3.36 2.07 1.59
Debt to NOPAT
-4.37 -4.15 -4.77 -9.18 -65.30 5.69 4.10 7.88 4.97 2.33 1.68
Net Debt to NOPAT
-4.01 -3.66 -3.10 -5.91 -35.76 2.21 2.42 4.58 1.08 -0.16 0.00
Long-Term Debt to NOPAT
-3.83 -3.61 -4.12 -7.87 -55.56 4.80 3.41 6.49 4.04 1.91 1.39
Altman Z-Score
1.59 1.38 1.26 1.90 2.18 2.84 2.69 2.45 3.11 4.51 4.47
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
2.71 2.37 3.11 3.41 4.12 3.85 4.21 4.26 4.82 4.75 4.61
Quick Ratio
0.86 0.72 1.37 1.71 2.06 1.88 1.61 1.82 2.43 2.65 2.41
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.55 1.77 2.43 2.30 1.84 0.29 -1.89 1.91 5.50 4.74 3.62
Operating Cash Flow to CapEx
594.84% 525.35% -723.13% -1.55% 478.30% 1,032.17% -199.75% 288.42% 2,136.60% 411.35% 56.19%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.49 0.54 0.54 0.60 0.62 0.64 0.62 0.63 0.67 0.66 0.71
Accounts Receivable Turnover
9.03 13.47 11.43 8.90 9.15 13.06 11.42 7.69 9.91 11.63 11.20
Inventory Turnover
2.29 2.32 2.35 2.49 2.52 2.27 1.90 1.98 2.14 2.11 2.00
Fixed Asset Turnover
0.77 0.85 0.88 1.00 1.05 1.10 1.11 1.19 1.31 1.34 1.44
Accounts Payable Turnover
7.94 7.45 8.03 8.05 8.90 6.87 6.79 6.80 8.25 6.79 7.15
Days Sales Outstanding (DSO)
40.41 27.11 31.94 41.03 39.90 27.94 31.96 47.47 36.83 31.39 32.58
Days Inventory Outstanding (DIO)
159.53 157.66 155.08 146.81 144.65 160.90 192.07 184.54 170.24 173.18 182.59
Days Payable Outstanding (DPO)
45.96 49.03 45.48 45.32 40.99 53.15 53.72 53.68 44.22 53.79 51.06
Cash Conversion Cycle (CCC)
153.98 135.75 141.55 142.53 143.55 135.70 170.30 178.32 162.84 150.78 164.11
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
35 33 34 34 35 34 35 32 31 31 33
Invested Capital Turnover
0.60 0.67 0.68 0.75 0.78 0.84 0.81 0.83 0.91 0.95 0.97
Increase / (Decrease) in Invested Capital
-0.76 -2.74 -2.83 -1.69 -0.73 0.28 1.90 -1.95 -3.54 -2.85 -2.65
Enterprise Value (EV)
52 48 37 49 49 67 62 61 59 92 91
Market Capitalization
41 38 30 42 43 63 57 56 57 92 91
Book Value per Share
$3.18 $3.00 $3.24 $3.37 $3.23 $3.31 $3.29 $2.99 $3.22 $3.47 $3.61
Tangible Book Value per Share
$3.16 $2.99 $3.22 $3.36 $3.22 $3.30 $3.28 $2.98 $3.21 $3.46 $3.60
Total Capital
36 35 37 38 39 40 39 36 38 40 41
Total Debt
12 11 11 11 10 9.80 9.49 9.10 8.70 8.30 7.90
Total Long-Term Debt
10 9.80 9.42 9.04 8.65 8.26 7.90 7.49 7.07 6.80 6.52
Net Debt
11 9.94 7.09 6.78 5.57 3.80 5.60 5.29 1.89 -0.56 -0.02
Capital Expenditures (CapEx)
0.07 0.11 0.09 0.20 0.33 0.16 0.59 0.17 0.17 0.73 1.35
Debt-free, Cash-free Net Working Capital (DFCFNWC)
7.65 6.37 7.09 8.37 8.97 8.23 11 11 9.76 9.29 10
Debt-free Net Working Capital (DFNWC)
8.61 7.70 11 12 14 14 14 15 17 18 18
Net Working Capital (NWC)
7.16 6.24 9.42 11 12 13 13 13 15 17 17
Net Nonoperating Expense (NNE)
0.23 0.56 0.30 0.10 -0.33 0.07 0.15 2.81 0.02 0.05 0.02
Net Nonoperating Obligations (NNO)
11 9.94 7.09 6.78 5.57 3.80 5.60 5.29 1.89 -0.56 -0.02
Total Depreciation and Amortization (D&A)
0.68 0.68 0.69 0.68 0.69 0.68 0.71 0.71 0.53 0.47 0.46
Debt-free, Cash-free Net Working Capital to Revenue
35.93% 27.45% 29.75% 31.59% 32.86% 29.10% 37.93% 38.96% 32.62% 30.29% 31.21%
Debt-free Net Working Capital to Revenue
40.44% 33.15% 45.73% 45.78% 49.70% 50.31% 51.92% 52.73% 55.38% 59.17% 55.04%
Net Working Capital to Revenue
33.66% 26.86% 39.52% 40.13% 44.15% 44.88% 46.19% 46.91% 49.94% 54.26% 50.88%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.06) ($0.20) ($0.09) $0.09 $0.16 $0.06 ($0.02) ($0.32) $0.21 $0.20 $0.10
Adjusted Weighted Average Basic Shares Outstanding
7.75M 7.81M 8.16M 8.17M 8.98M 9.03M 9.05M 9.03M 9.05M 9.06M 9.08M
Adjusted Diluted Earnings per Share
($0.06) ($0.20) ($0.09) $0.09 $0.16 $0.06 ($0.02) ($0.32) $0.21 $0.20 $0.10
Adjusted Weighted Average Diluted Shares Outstanding
7.75M 7.81M 8.16M 8.17M 8.98M 9.03M 9.05M 9.03M 9.05M 9.19M 9.30M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
7.81M 7.83M 8.91M 8.98M 0.00 0.00 9.05M 9.05M 9.05M 9.08M 9.09M
Normalized Net Operating Profit after Tax (NOPAT)
-0.21 -0.97 -0.40 0.61 1.12 0.57 0.01 -0.04 1.96 1.89 0.67
Normalized NOPAT Margin
-2.89% -17.74% -6.69% 7.92% 13.84% 8.80% 0.26% -0.53% 18.89% 26.27% 8.34%
Pre Tax Income Margin
-6.01% -27.96% -11.65% 6.72% 17.96% 7.82% -2.46% -37.32% 18.87% 26.17% 11.63%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% -13.53% -123.19% 11.06% 3.62% -6.53% -4.57% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ImmuCell’s financial performance has improved substantially entering 2026, although the latest quarter showed weaker sales and margins than the prior quarter. Revenue increased to $7.2 million in Q2 2026 from $6.4 million in Q2 2025, while the company remained profitable with net income of $1.8 million, or $0.20 per diluted share. This compares with net income of $502,000, or $0.06 per diluted share, in Q2 2025.

The improvement is especially apparent across the first half of 2026. ImmuCell generated approximately $17.5 million of revenue and $3.8 million of net income during the first two quarters, compared with roughly $14.5 million of revenue and $2.0 million of net income in the comparable 2025 period. However, Q2 revenue declined approximately 30.6% sequentially from Q1, and gross margin fell to about 33.9% from 44.9% in Q1.

Cash generation has also strengthened. Operating cash flow was $3.0 million in Q2 2026 and $3.6 million in Q1, compared with $1.6 million in each of the first two quarters of 2025. Cash and equivalents reached $8.9 million at June 30, 2026, while the company continued making debt repayments.

  • Revenue growth: Q2 2026 revenue increased approximately 11.5% year over year, continuing the broader recovery from the weaker results reported during parts of 2024 and 2025.
  • Return to sustained profitability: ImmuCell reported two consecutive quarters of net income above $1.8 million in 2026, following a $2.8 million loss in Q4 2025 and losses in several earlier periods.
  • Strong operating cash flow: Operating cash flow totaled approximately $6.6 million during the first half of 2026, providing internally generated funds for investment, debt service and working capital.
  • Improved liquidity: Cash increased to $8.9 million from $6.8 million at the end of Q1 2026 and $6.0 million at June 30, 2025. Current assets of $21.1 million substantially exceeded current liabilities of $4.4 million.
  • Debt reduction: Total short- and long-term debt declined to approximately $8.3 million at June 30, 2026, from about $9.9 million a year earlier, which should gradually reduce financial risk and interest expense.
  • Higher equity base: Total common equity increased to $31.4 million from $29.9 million at the end of Q3 2025, supported by recent profitability and improved retained earnings.
  • Sequential volatility: Q1 2026 was unusually strong, with $10.4 million of revenue and $4.7 million of gross profit, while Q2 revenue fell to $7.2 million and gross profit declined to $2.4 million. Investors should watch whether Q2 reflects normal seasonality or a broader slowdown.
  • Working-capital intensity: Inventory stood at $9.1 million, representing a significant portion of current assets. This provides product availability but could tie up cash if sales growth slows or inventory turns deteriorate.
  • Margin compression: Q2 2026 gross margin was approximately 33.9%, down from 43.7% in Q2 2025 and 44.9% in Q1 2026. Higher production costs or an unfavorable product mix could pressure future earnings.
  • Reliance on unusual operating income: Q2 included $2.0 million of “other operating income,” which reduced reported operating expenses and helped produce $1.9 million of operating income. Because this item may not recur, reported profitability may overstate the company’s underlying recurring operating performance.

Overall, ImmuCell’s balance sheet and cash flow trends are improving, and the company has moved from recurring losses to meaningful profitability in early 2026. The main risks are the sharp sequential decline in Q2 sales, lower gross margins, high inventory and the sustainability of the unusual operating-income benefit. Retail investors should focus on whether future quarters can maintain positive operating cash flow and profitability without relying on one-time or nonrecurring items.

11/18/26 12:40 AM ETAI Generated. May Contain Errors.

ImmuCell Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ImmuCell's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

ImmuCell's net income appears to be on a downward trend, with a most recent value of -$1.04 million in 2025, compared with $1.21 million in 2015. The previous period was -$2.16 million in 2024. View ImmuCell's forecast to see where analysts expect ImmuCell to go next.

ImmuCell's total operating income in 2025 was $1.65 million, based on the following breakdown:
  • Total Gross Profit: $11.45 million
  • Total Operating Expenses: $9.80 million

Over the last 10 years, ImmuCell's total revenue changed from $10.23 million in 2015 to $27.64 million in 2025, a change of 170.3%.

In the past 12 quarters, ImmuCell's cash and equivalents has ranged from $960.35 thousand in Q1 2024 to $8.86 million in Q2 2026, and is currently $7.91 million as of their latest financial filing in Q3 2026.

ImmuCell had total debt of $9.10 million at the end of 2025, a 13.7% decrease from 2024, and a 185.6% increase since 2015.

Over the last 10 years, ImmuCell's book value per share changed from 3.47 in 2015 to 2.99 in 2025, a change of -13.9%.



Financial statements for NASDAQ:ICCC last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners